Chemomab Therapeutics Ltd (NASDAQ:CMMB) My opinion remains intact about this small bio cap. I will not sell a single share below $40 unless something bad happens, but that does not seem to be the case according to the recent news and reports. The stock has been falling on very low volume. The company has a great pipeline and the existing cash position is expected to fund the Company's current operating plan until mid 2023. The stock market is a device for transferring money from the impatient to the patient" Warren Buffet. I remember being called a pumper on PLUG or MARA when the stocks were trading at $2. NOTE: The 2 Wall Street analysts offering 12-month price forecasts for Chemomab Therapeutics Ltd have a median target of 43.50, with a high estimate of 45.00 and a low estimate of 42.00